mTORC2 regulates PGE2-mediated endothelial cell survival and migration

Biochemical and Biophysical Research Communications

Volumn 372, Issue 4, 2008, Pages 875-879

  Dada, Shirine ^a   Demartines, Nicolas ^b   Dormond, Olivier ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Akt; Angiogenesis; Endothelial cell; Migration; mTOR; PGE2; Rac; Rapamycin; Survival

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROSTAGLANDIN E2; PROTEIN KINASE B; RAC PROTEIN; RAPAMYCIN; SMALL INTERFERING RNA; MTORC1 PROTEIN, HUMAN; MULTIENZYME COMPLEX; TRANSCRIPTION FACTOR;

ARTICLE; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RAPTOR; ANGIOGENESIS; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY;

RAPTORES;

CELL MOVEMENT; CELL SURVIVAL; DINOPROSTONE; ENDOTHELIAL CELLS; HUMANS; MULTIENZYME COMPLEXES; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; RAC GTP-BINDING PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 45449106969     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.05.154     Document Type: Article

References (26)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., and Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5 (1999) 1418-1423
3. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
4. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60 (2000) 1306-1311
5. Dormond O., Foletti A., Paroz C., and Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. 7 (2001) 1041-1047
6. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., Richmond A., Strieter R., Dey S.K., and DuBois R.N. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 203 (2006) 941-951
7. Kamiyama M., Pozzi A., Yang L., DeBusk L.M., Breyer R.M., and Lin P.C. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 25 (2006) 7019-7028
8. Rao R., Redha R., Macias-Perez I., Su Y., Hao C., Zent R., Breyer M.D., and Pozzi A. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J. Biol. Chem. 282 (2007) 16959-16968
9. Finetti F., Solito R., Morbidelli L., Giachetti A., Ziche M., and Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J. Biol. Chem. 283 (2008) 2139-2146
10. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
11. Sarbassov D.D., Ali S.M., and Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17 (2005) 596-603
12. Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., and Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95 (1998) 1432-1437
13. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. Rictor, a novel binding partner of mTOR defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
14. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., and Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6 (2004) 1122-1128
15. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
16. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., and Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
17. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M.C., Rafii S., and Pandolfi P.P. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442 (2006) 779-785
18. Vinals F., Chambard J.C., and Pouyssegur J. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J. Biol. Chem. 274 (1999) 26776-26782
19. Dormond O., Madsen J.C., and Briscoe D.M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 282 (2007) 23679-23686
20. Dormond O., Bezzi M., Mariotti A., and Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 277 (2002) 45838-45846
21. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
22. Birukova A.A., Zagranichnaya T., Alekseeva E., Bokoch G.M., and Birukov K.G. Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J. Cell. Physiol. (2007)
23. Hernandez-Negrete I., Carretero-Ortega J., Rosenfeldt H., Hernandez-Garcia R., Calderon-Salinas J.V., Reyes-Cruz G., Gutkind J.S., and Vazquez-Prado J. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J. Biol. Chem. 282 (2007) 23708-23715
24. Masri J., Bernath A., Martin J., Jo O.D., Vartanian R., Funk A., and Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67 (2007) 11712-11720
25. Jindra P.T., Jin Y.P., Jacamo R., Rozengurt E., and Reed E.F. MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem. Biophys. Res. Commun. (2008)
26. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., and Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006) 859-871